Focused on tissue protection, repair, and regeneration, this clinical-stage biopharmaceutical company develops novel pharmaceuticals, specifically Tβ4-based drug candidates, to address organ damage from various pathologies. Active partnerships in major territories aid in advancing clinical trials for its products, notably in ophthalmic and cardiovascular applications.